Invitation to participate in a global Delphi study on cachexia in adult palliative care patients
The study sponsors are looking for collaborators whose expertise would be valuable in formulating recommendations that will improve care worldwide.
The international Delphi study aims to build consensus on best practice in the management of cachexia in palliative care. Cachexia is a complex metabolic syndrome that significantly affects patients with advanced disease.
The study's team of promoters consists of Matteo Moroni (principal investigator), AUSL Romagna, Luca Ghirotto (head of a quality research unit, qualitative approach).
The Italian version of this Delphi study will soon be published in Tumori Journal under the reference: Attitudes and beliefs of Italian palliative care experts regarding cachexia: a Delphi study (DOI: 10.1177/03008916261418900/ ID: TMJ-25-0505.R1). 2.1
The team is looking for healthcare professionals with at least 10 years' experience in palliative medicine or palliative care, ideally with a qualification or competence in clinical research. Dieticians and social workers with similar experience are also welcome to ensure a multidisciplinary perspective. Their contribution will help to advance international standards in the management of cachexia in palliative care and will be acknowledged in subsequent publications.
The aim of the participation sought is to ensure consensus. It involves completing two sets of questionnaires, a third may be necessary. Only commit if you can complete all rounds, as failure to complete subsequent rounds could compromise the validity of the study. Each series will last approximately 20 to 30 minutes. - Series 1 (February): approx. 20-30 minutes - Series 2 (April/May): approx. 20-30 minutes - Series 3 (if required): approx. 20-30 minutes.
Contact:
For information or requests for further details, please contact:
Matteo MORONI
matteo.moroni@auslromagna.it
To confirm your availability and consent, please complete this form:
https://forms.office.com/e/xXriB4Mjc0
- This study used anonymous responses to questions about patient preferences, without data collection. Procedures complied with the GDPR (General Data Protection Regulation - European Directive 2016/679), and participants were provided with detailed information about this.